Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Rentschler Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, Rentschler Biopharma’s ATMP site will support the bioprocess development of AAV material for planned pre-clinical testing of Ikarovec’s novel AAV-based therapy for the treatment of geographic atrophy.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 06, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Rentschler Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Visionary Ventures
Deal Size : $11.9 million
Deal Type : Series A Financing
Re-vana Therapeutics Raises $11.9 Million In Series A Financing
Details : The proceeds will advance the development of Re-Vana’s novel and proprietary photo-crosslinked EyeLief®, EyeLief-SD™ and OcuLief® biodegradable drug delivery technologies and will enable expansion of the company’s operations and development teams...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 12, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Visionary Ventures
Deal Size : $11.9 million
Deal Type : Series A Financing
Lead Product(s) : OLX301D
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : OliX Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, LGC will produce the active pharmaceutical ingredients for the preclinical and clinical study of OLX301D program, for the treatment of sub-retinal fibrosis and wet macular degeneration.
Product Name : OLX301D
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 16, 2020
Lead Product(s) : OLX301D
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : OliX Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : UKi2S
Deal Size : $3.2 million
Deal Type : Funding
Ophthalmic gene therapy company launches with £2.5m seed cash
Details : The cash will primarily take the company’s lead programme, a multicistronic gene therapy for diabetic macular edema (DME), to IND-enabling studies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 02, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : UKi2S
Deal Size : $3.2 million
Deal Type : Funding